Replies to post #105 on Nektar Therapeutics (NKTR)

[dangerx]

Good stock to watch for the time being. I currently have 3 pharmaceutical stocks on my radar and the stocks for all 3 seem to have a similar niche within the industry. I see the downside potential of Nektar being similar to Anthera Pharmaceuticals (AN*TH) which dropped from ~$7 to $2 after missing on a late stage clinical trial. The upside potential looks similar to Vivus pharmaceuticals (VV*US), which jumped from ~$8 to ~$26 after approval on two drug candidates. Pharmaceutical R&D is almost always a gamble, but by the time investors know whether a drug candidate is going to make it to the market, it will be too late to get in a position to maximize profit (or minimize loss) GLTA!